Profile data is unavailable for this security.
About the company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
- Revenue in USD (TTM)0.00
- Net income in USD-50.53m
- Incorporated2017
- Employees57.00
- LocationDesign Therapeutics Inc6005 Hidden Valley Road, Suite 110CARLSBAD 92011United StatesUSA
- Phone+1 (858) 293-4900
- Fax+1 (302) 636-5454
- Websitehttps://www.designtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 302.52m | 203.00 | -- | 0.559 | -- | 1.59 | -0.2824 | -0.2824 | 3.29 | 9.29 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | -- | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
Tscan Therapeutics Inc | 12.20m | -104.41m | 306.19m | 175.00 | -- | 1.20 | -- | 25.10 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Taysha Gene Therapies Inc | 12.87m | -114.34m | 307.41m | 52.00 | -- | 2.77 | -- | 23.88 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
AVITA Medical Inc | 60.04m | -57.32m | 310.58m | 207.00 | -- | 25.62 | -- | 5.17 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -70.21m | 312.65m | 161.00 | -- | 1.40 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Mersana Therapeutics Inc | 29.94m | -104.77m | 315.27m | 123.00 | -- | 37.41 | -- | 10.53 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
AC Immune SA | 17.69m | -69.13m | 316.61m | 133.00 | -- | 2.25 | -- | 17.89 | -0.7332 | -0.7332 | 0.1911 | 1.42 | 0.0787 | -- | 28.76 | 133,041.40 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Tango Therapeutics Inc | 43.38m | -123.40m | 316.88m | 140.00 | -- | 1.38 | -- | 7.30 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 318.40m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
Rezolute Inc | 0.00 | -68.46m | 323.32m | 59.00 | -- | 2.46 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 328.01m | 10.00 | -- | 3.34 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -50.53m | 330.10m | 57.00 | -- | 1.26 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Codexis Inc | 64.45m | -62.09m | 332.02m | 174.00 | -- | 4.52 | -- | 5.15 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 338.56m | 157.00 | -- | 0.51 | -- | 9.67 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
enGene Holdings Inc | 0.00 | -123.44m | 349.30m | 33.00 | -- | 1.52 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Lyell Immunopharma Inc | 54.00k | -210.26m | 358.79m | 224.00 | -- | 0.5512 | -- | 6,644.33 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Logos Global Management LPas of 09 Aug 2024 | 4.22m | 7.45% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 2.01m | 3.54% |
Baker Bros. Advisors LPas of 30 Jun 2024 | 1.70m | 2.99% |
Tang Capital Management LLCas of 30 Jun 2024 | 1.48m | 2.62% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.27m | 2.24% |
Almitas Capital LLCas of 30 Jun 2024 | 1.25m | 2.21% |
Point72 Asset Management LPas of 30 Jun 2024 | 992.09k | 1.75% |
Geode Capital Management LLCas of 30 Jun 2024 | 707.97k | 1.25% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 695.42k | 1.23% |
Millennium Management LLCas of 30 Jun 2024 | 610.80k | 1.08% |